Revelation Biosciences Announces 1-for-7 Reverse Split for Nasdaq Compliance
Revelation Biosciences, Inc. (REVB) plans to enact a 1-for-7 reverse stock split on the morning of Oct. 20, 2026. Following the consolidation, the company will keep its REVB ticker symbol while adopting a new CUSIP identifier. Any fractional shares resulting from the ratio adjustment will be rounded up, and equity awards will be adjusted proportionally. Shares were recently trading at $0.7622, up 5.91% for the session.
The action is intended to raise the stock price so the firm can meet Nasdaq minimum bid standards, which require shares to maintain at least a $1.00 price. Failing to fulfill this threshold creates listing risks that could eventually lead to delisting.
To maintain its exchange presence over the longer term, the company will need a sustained share price above the requirement along with clinical and financial milestones.
Key points
- Revelation Biosciences, Inc. (REVB) will implement a 1-for-7 reverse stock split on Oct. 20, 2026.
- The split aims to elevate the share price above Nasdaq's $1.00 minimum bid threshold.
- The ticker symbol will remain REVB, while the stock receives a new CUSIP number.
- Fractional shares will be rounded up, and equity awards will be adjusted on a proportional basis.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
When will the Revelation Biosciences reverse split take effect?
The 1-for-7 reverse stock split is scheduled to take effect on the morning of Oct. 20, 2026.
Why is Revelation Biosciences conducting a reverse stock split?
The split is designed to increase the share price to regain compliance with Nasdaq minimum bid price requirements.
Will the REVB ticker symbol change after the split?
No, shares will continue trading under the ticker symbol REVB, though a new CUSIP number will be assigned.